Haleon (LON:HLN) Issues Earnings Results

Haleon (LON:HLN) posted its earnings results on Thursday. The company reported GBX 8.60 EPS for the quarter, Digital Look Earnings reports. Haleon had a net margin of 15.11% and a return on equity of 10.30%.

Haleon Stock Performance

Shares of HLN traded down GBX 11.10 during trading hours on Thursday, hitting GBX 368.60. The company’s stock had a trading volume of 27,201,275 shares, compared to its average volume of 28,030,555. The business has a 50 day simple moving average of GBX 348.92 and a two-hundred day simple moving average of GBX 363.11. Haleon has a 52-week low of GBX 317.80 and a 52-week high of GBX 416.10. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. The company has a market cap of £32.46 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 1.49 and a beta of 0.24.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and set a GBX 325 target price on shares of Haleon in a research note on Wednesday, July 1st. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a report on Thursday, April 30th. JPMorgan Chase & Co. lowered their price objective on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Berenberg Bank reissued a “buy” rating and set a GBX 512 target price on shares of Haleon in a research report on Thursday, April 30th. Finally, Jefferies Financial Group lowered their price target on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of GBX 393.67.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.